Osteogenic growth peptide 10-14 L

Drug Profile

Osteogenic growth peptide 10-14 L

Alternative Names: OGP 10-14 L

Latest Information Update: 18 Mar 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Abiogen Pharma
  • Class Peptides
  • Mechanism of Action Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelofibrosis

Highest Development Phases

  • Discontinued Myelofibrosis; Stem cell mobilisation

Most Recent Events

  • 11 May 2006 Phase-I/II clinical trials in Stem cell mobilisation in Italy (IV-injection)
  • 11 May 2006 No development reported - Phase-I for Myelofibrosis in Italy (IV-injection)
  • 06 Oct 2003 Osteogenic growth peptide 10-14 L has received Orphan Drug Status for Myelofibrosis in Italy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top